U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07458425) titled 'The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk' on Jan. 06.
Brief Summary: This is a two-cohort (screen naive vs screen established), prospective, longitudinal, single-center clinical study design that will provide data to comprehensively evaluate patient-reported outcomes of Artificial Intelligence (AI) based prediction of an individual's risk of developing lung cancer over the next 3 years.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Lung Cancer
Intervention:
DIAGNOSTIC_TEST: Artificial Intelligence (AI) test
Individuals eligible for lung cancer screening b...